<DOC>
	<DOCNO>NCT01110044</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity birth dose GSK Biologicals ' reduced-antigen-content tri-component pertussis ( 251154 ) vaccine follow routine paediatric vaccination .</brief_summary>
	<brief_title>Study Birth Dose GlaxoSmithKline Biologicals ' 251154 Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /LAR ( ) comply requirement protocol . Written inform consent obtain parent ( ) /LAR ( ) subject . A male female infant , include , 2 5 day age time randomisation . Subjects born uncomplicated gestation period 36 42 week inclusive . Subjects bear mother seronegative hepatitis B surface antigen . Subjects birth weight &gt; = 2.5 kg . Subjects 5minute Apgar score &gt; = 7 . Healthy subject establish medical history clinical examination Use investigational nonregistered product study vaccine since birth , plan use study period . Born mother know suspect seropositive HIV . Family history congenital hereditary immunodeficiency . Children care.. Neonatal jaundice require systemic treatment . Administration immunoglobulins and/or blood product since birth plan administration study period . Administration vaccine since birth plan administration study period exception inactivate influenza vaccine . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . History seizures progressive neurological disease . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . History reaction hypersensitivity likely exacerbate component vaccine . Major congenital defect serious chronic illness , include perinatal brain damage . The following condition temporary selflimiting , subject may vaccinate condition resolve exclusion criterion meet : • Current febrile illness temperature &gt; = 38.5°C oral axillary setting , &gt; = 39.0°C rectal setting , moderate severe illness within 24 hour study vaccine administration .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Days</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Neonatal vaccination</keyword>
</DOC>